

1 **Title page**

2 **Title:** Potential Biases in Test-Negative Design Studies of COVID-19 Vaccine Effectiveness  
3 Arising from the Inclusion of Asymptomatic Individuals

4 **Authors:** Edgar Ortiz-Brizuela<sup>1,2</sup>, Mabel Carabali<sup>1</sup>, Cong Jiang<sup>3</sup>, Joanna Merckx<sup>1</sup>, Denis Talbot<sup>4</sup>,  
5 \*Mireille E. Schnitzer<sup>3,5,1</sup>

6 **Affiliations:**

7 1. Department of Epidemiology, Biostatistics, and Occupational Health, McGill University,  
8 Montreal, Quebec, Canada.

9 2. Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición Salvador  
10 Zubirán, Mexico City, Mexico.

11 3. Faculty of Pharmacy, Université de Montréal, Montréal, Québec, Canada.

12 4. Department of Social and Preventive Medicine, Université Laval, Quebec, Quebec, Canada.

13 5. Department of Social and Preventive Medicine, School of Public Health, Université de  
14 Montréal, Montréal, Quebec, Canada.

15 **Corresponding author:** Mireille E. Schnitzer

16 **Contact information:**

17 Address: Faculty of Pharmacy, Université de Montréal, Montréal, QC, Canada.

18 Tel: 514 343-6111, extension: 0302

19 Email: [mireille.schnitzer@umontreal.ca](mailto:mireille.schnitzer@umontreal.ca)

20 **Word Count:**

21 Abstract: 195; Text: 3934.

## 1 **Abstract**

2 The test-negative design (TND) is a popular method for evaluating vaccine effectiveness (VE). A  
3 "classical" TND study includes symptomatic individuals tested for the disease targeted by the  
4 vaccine to estimate VE against symptomatic infection. However, recent applications of the TND  
5 have attempted to estimate VE against infection by including all tested individuals, regardless of  
6 their symptoms. In this article, we employ directed acyclic graphs and simulations to investigate  
7 potential biases in TND studies of COVID-19 VE arising from the use of this "alternative"  
8 approach, particularly when applied during periods of widespread testing. We show that the  
9 inclusion of asymptomatic individuals can potentially lead to collider stratification bias,  
10 uncontrolled confounding by health and healthcare-seeking behaviors (HSBs), and differential  
11 outcome misclassification. While our focus is on the COVID-19 setting, the issues discussed may  
12 also be relevant in the context of other infectious diseases. This may be particularly true in  
13 scenarios where there is either a high baseline prevalence of infection, a strong correlation between  
14 HSBs and vaccination, different testing practices for vaccinated and unvaccinated individuals, or  
15 settings where both the vaccine under study attenuates symptoms of infection and diagnostic  
16 accuracy is modified by the presence of symptoms.

## 17 **Keywords**

18 Test-negative design, COVID-19, vaccine, effectiveness, asymptomatic, SARS-CoV-2,  
19 simulation study, collider bias, confounding, misclassification.

## 20 Introduction

21 The post-licensure evaluation of COVID-19 vaccine effectiveness (VE), defined as the effect of  
22 vaccination on the risk of an infection-related outcome,<sup>1</sup> has provided crucial insights into  
23 questions not addressed through randomized clinical trials.<sup>2-4</sup> Among the study designs used to  
24 estimate VE, the test-negative design (TND) has gained popularity, in part because of its rapid and  
25 seemingly straightforward implementation.<sup>2,5,6</sup> In a "classical" TND study, symptomatic  
26 individuals tested for the disease targeted by the vaccine are prospectively selected, for example,  
27 from surveillance centers or hospitals.<sup>5-8</sup> Then, VE against symptomatic infection is estimated by  
28 comparing the odds of vaccination between patients with positive and negative test results using  
29 logistic regression.<sup>5,7,8</sup> However, recent literature<sup>9-20</sup> has also applied the term TND to studies  
30 aiming to estimate VE against infection by including all tested individuals, regardless of their  
31 symptom status (hereafter referred to as "alternative" TND) — for a clearer distinction between  
32 classical and alternative TND, see **Box 1**. Nonetheless, this approach may introduce additional  
33 threats to validity and warrants a more comprehensive evaluation.<sup>21</sup>

34 In this article, we investigate potential biases in TND studies of COVID-19 VE arising from the  
35 use of this "alternative" approach, particularly when applied during periods of widespread testing.  
36 We begin by discussing the identifiability of two causal target parameters: 1) the risk ratio (RR)  
37 for medically attended and laboratory-confirmed symptomatic COVID-19 relative to vaccination  
38 status, referred to as  $RR_{COVID}$  (the target parameter for the classical TND), and 2) the RR for  
39 SARS-CoV-2 infection relative to vaccination status, referred to as  $RR_{infect}$  (the target parameter  
40 for the alternative TND) — note that throughout this manuscript we use the expression  
41 "symptomatic COVID-19" to emphasize the difference between symptomatic and asymptomatic

42 infections. We conclude with a simulation study that aims to estimate and compare the magnitude  
43 of the bias in the odds ratio (OR) estimates for medically attended and laboratory-confirmed  
44 symptomatic COVID-19 ( $OR_{COVID}$ ) and the OR for SARS-CoV-2 infection ( $OR_{infect}$ ), relative to  
45 their respective target parameters ( $RR_{COVID}$  and  $RR_{infect}$ ), under scenarios where a classical TND  
46 is considered valid.

### 47 **Identifiability of target parameters**

48 In this section, we use causal directed acyclic graphs (DAGs) to examine the identifiability of the  
49 target parameters ( $RR_{COVID}$  and  $RR_{infect}$ ).<sup>22</sup> By "identifiability," we refer to the ability to express  
50 a counterfactual quantity as a function of the distribution of observed data, implying the absence  
51 of systematic biases.<sup>23,24</sup> However, before delving into the specifics of target parameter  
52 identifiability, and to facilitate a better understanding, we introduce the reader to a DAG based on  
53 previous work<sup>7,8,21,25,26</sup> that illustrates the assumed causal relationships between relevant variables  
54 in TND studies of COVID-19 VE, whether classical or alternative (**Box 2**).

#### 55 *The case of the classical TND*

56 In this context, if the test-negative state (having some illness that presents with COVID-19-like  
57 symptoms – such as an infection not targeted by the vaccine ( $I = 1$ ) – and testing) and the  
58 vaccination status are independent conditional on covariates, the case-status OR ( $OR_{COVID}$ ) relative  
59 to vaccination status — derived from a correctly specified multivariable logistic regression model  
60 — provides an unbiased estimate of its target parameter: the conditional RR for medically attended  
61 and laboratory-confirmed symptomatic COVID-19 ( $I = 2, S = 1, T = 1$ ) relative to vaccination  
62 status ( $RR_{COVID}$ ).<sup>8,27</sup> Mathematical definitions for  $OR_{COVID}$  and  $RR_{COVID}$  are provided in **Box 3**. In

63 hospital-based TND studies,  $RR_{COVID}$  represents the risk ratio for medically attended infections  
64 leading to hospitalization (where  $T$  stands for "hospitalized and tested due to symptoms").<sup>8</sup> On the  
65 other hand, in outpatient-based TND studies,  $RR_{COVID}$  represents the risk ratio for medically  
66 attended infections in outpatient settings (where  $T$  stands for "accessed care and tested").

67 Importantly, unlike some traditional case-control studies, the TND does not require the rare disease  
68 assumption for the OR to approximate the RR.<sup>8</sup> It is also noteworthy that the  $OR_{COVID}$  estimate is  
69 often re-expressed as VE using the estimator:  $\widehat{VE} = (1 - \widehat{RR}) \times 100$ .<sup>5</sup> However, to avoid  
70 ambiguity, throughout this manuscript and unless otherwise specified, the term VE will continue  
71 to refer to any causal effect of vaccination on the risk of an infection-related outcome, regardless  
72 of the outcome assessed.<sup>1</sup>

73 In addition, the estimands mentioned above can be given a causal interpretation if the identifiability  
74 assumptions are also met (**Appendix S2**).<sup>8,28,29</sup> One such assumption, known as conditional  
75 exchangeability, implies that all common causes of vaccination status ( $V$ ) and outcome (medically  
76 attended and laboratory-confirmed symptomatic SARS-CoV-2 infection [ $I = 2, S = 1, T = 1$ ])  
77 have been measured and appropriately accounted for in the analysis.<sup>8,28-30</sup> However, among these  
78 common causes, an individual's health and healthcare-seeking behaviors (HSBs) are inherently  
79 unmeasured.<sup>21</sup> In a best-case scenario, if HSBs were deterministic (meaning that individuals who  
80 exhibit these behaviors would always seek medical care when ill, while individuals who do not  
81 exhibit HSBs would not), a classical TND study could mitigate bias related to this variable by  
82 restricting the study population to individuals who have sought medical attention and are therefore  
83 assumed to exhibit HSBs ( $H = 1$ ).<sup>5,7</sup> Although this scenario seems unlikely in real-world settings,  
84 where these behaviors may only modify the probability of seeking medical care, classical TND

85 studies could still offer better control for confounding by HSBs than other observational study  
86 designs such as cohorts or traditional case-control studies.<sup>7,8</sup>

87 To illustrate this point, **Figure 1(a)** shows a DAG that represents an ideal scenario for a classical  
88 TND study evaluating VE against medically attended and laboratory-confirmed symptomatic  
89 COVID-19. By "ideal", we mean that the study is conducted in a population where HSBs are  
90 deterministic and only perfect tests are used (with 100% sensitivity and specificity). In this study,  
91 the effect of interest is represented by the path  $V \rightarrow I \bullet S \bullet T$ . The square shapes of the nodes  $S$ ,  $T$ ,  
92 and  $H$  indicate that the study sample is restricted to symptomatic and tested individuals who sought  
93 medical care and therefore exhibit HSBs ( $S = 1, T = 1, H = 1$ ). Conditioning on HSBs is critical  
94 because it not only allows control of confounding through the path  $V \leftarrow H \rightarrow I$  but also blocks  
95 other biasing paths (e.g.,  $V \leftarrow H \rightarrow T \leftarrow S \leftarrow I$ ) that were opened by conditioning on colliders such  
96 as testing ( $T$ ). In other words, restricting the study sample in a classical TND study to symptomatic  
97 and tested individuals is essential to prevent (or minimize) confounding and collider-stratification  
98 bias by HSBs,<sup>7</sup> and thus, to identify the  $RR_{COVID}$ .

99 *The case of the alternative TND*

#### 100 Potential for collider stratification bias and uncontrolled confounding by HSBs

101 Having studied the classical TND, we now turn to the challenges presented by the alternative  
102 approach. In this scenario, since the study sample includes all tested individuals, regardless of  
103 symptoms, the target parameter is no longer the  $RR_{COVID}$ . Instead, it is the conditional RR for  
104 SARS-CoV-2 infection relative to vaccination status ( $RR_{infect}$ ), represented by the path  $V \rightarrow I$ .  
105 Mathematical definitions for  $OR_{infect}$  and  $RR_{infect}$  are given in **Box 3**.

106 To assess the identifiability of this target parameter, it is crucial to identify the specific drivers of  
107 testing leading to selection. Importantly, these drivers may have varied across settings, depending  
108 on the stage of the pandemic and the prevailing indications for testing.<sup>31,32</sup> For example, in a  
109 prospective, nonprobability-based, cross-sectional online survey of testing practices conducted  
110 between August 23, 2021, and March 12, 2022, among 418,279 U.S. adults aged  $\geq 18$  years, the  
111 most common reasons for testing, other than having symptoms, were exposure to COVID-19  
112 (23.1%), a prerequisite for travel (20.6%), and requirement for work or school (16.1%).<sup>31</sup> Given  
113 that some of these reasons were mandatory at various points in time, we can no longer assume that  
114 the study sample is limited to healthcare seekers,<sup>21</sup> and that the TND effectively controls for bias  
115 related to HSBs. This may also be relevant to some hospital-based TND studies, as some  
116 institutions implemented policies for universal screening on admission.<sup>33,34</sup>

117 We illustrate this point in the DAG shown in **Figure 1(b)**, which represents an alternative TND  
118 study of VE against SARS-CoV-2 infection. In this DAG, the circular shapes of the nodes HSBs  
119 ( $H$ ) and COVID-19-like symptoms ( $S$ ) indicate that we are no longer conditioning on these  
120 variables. As a result, several biasing paths are opened, leading to uncontrolled confounding by  
121 HSBs ( $V \leftarrow H \rightarrow I$ ; path 1 in **Figure S1**) and collider stratification bias ( $I \leftarrow H \rightarrow T \leftarrow S \leftarrow V$   
122 (path 2);  $V \rightarrow S \leftarrow I$  (path 3);  $I \leftarrow H \rightarrow T \leftarrow V$  (path 4);  $I \rightarrow S \rightarrow T \leftarrow V$  (path 5); and  $V \leftarrow H \rightarrow$   
123  $T \leftarrow S \leftarrow I$  (path 6)). In other words, the  $RR_{infect}$  is not identifiable in the alternative TND setting.

#### 124 Potential for differential outcome misclassification

125 Another perceived benefit of the TND is its potential to reduce outcome misclassification  
126 compared to traditional cohort or case-control studies.<sup>7,8</sup> This is primarily attributed to the  
127 restriction of the study sample to individuals with confirmed infection status.<sup>7,8</sup> However, the

128 inclusion of asymptomatic individuals in alternative TND studies could potentially compromise  
129 this apparent benefit and instead lead to differential misclassification of the outcome relative to  
130 the exposure status. The main reason for this is that while SARS-CoV-2 diagnostic tests have  
131 excellent specificity for diagnosing acute infection, their sensitivity is likely modified by the  
132 presence of symptoms.<sup>32</sup> For example, two studies comparing the diagnostic accuracy of SARS-  
133 CoV-2 tests, reported antigen test sensitivities in symptomatic individuals of 72.0% (95%  
134 confidence interval [95% CI], 63.7% to 79.0%) and 58.1% (95% CI, 40.2% to 74.1%) in those  
135 asymptomatic,<sup>35</sup> and nucleic acid amplification tests (NAATs) sensitivities in symptomatic  
136 individuals of 97.1% (95% CI, 96.7% to 97.3%) and 87.6% (95% CI, 85.2% to 89.6%) in those  
137 without symptoms.<sup>36</sup>

138 This concept is illustrated in the DAG shown in **Figure 1(c)**. This DAG introduces a new node for  
139 the measured infection status ( $I_x$ ), which may differ from its true value ( $I$ ). There is differential  
140 misclassification of the outcome ( $I$ ) relative to the exposure status ( $V$ ) because, as described in  
141 **Box 2**, COVID-19 vaccines ( $V$ ) may affect the presence of symptoms ( $S$ ),<sup>37-39</sup> which in turn  
142 modify the sensitivity of SARS-CoV-2 tests (represented by the path  $V \rightarrow S \rightarrow I_x$ ). This situation  
143 may be further complicated when considering that the selection of a specific test and its respective  
144 diagnostic performance, may depend on a number of additional factors.<sup>32</sup> These include the  
145 intended use of the test (i.e., screening versus confirmation, with molecular tests preferred for  
146 confirming diagnoses of acute infection in symptomatic individuals<sup>32,40</sup>), the time of infection  
147 onset,<sup>41</sup> the stage of the pandemic<sup>32</sup>, and the target population (e.g., travelers vs. frontline  
148 workers<sup>32</sup>). As a result, it is difficult to accurately predict the magnitude and direction of this bias  
149 without a comprehensive understanding of the causal structure underlying a given study.<sup>42</sup>



## 150 **Simulation study**

### 151 *Methods*

#### 152 Overview

153 We conducted a simulation study to estimate and compare the magnitude of the bias in  $OR_{COVID}$   
154 and  $OR_{infect}$  estimates — relative to their respective target parameters ( $RR_{COVID}$  and  $RR_{infect}$ ) —  
155 under scenarios where a classical TND is considered valid. For simplicity, all simulations assume  
156 causal consistency,<sup>30</sup> no interference,<sup>30</sup> positivity,<sup>30</sup> and no unmeasured confounding other than  
157 that related to HSBs. To assess the bias pathways, we divided the simulation study into two parts.  
158 First, we evaluate the potential for collider bias and uncontrolled confounding by HSBs, assuming  
159 perfect diagnostic tests. Second, we incorporate the potential for differential outcome  
160 misclassification by simulating an extreme scenario where symptomatic individuals are tested  
161 exclusively with NAATs, and asymptomatic individuals are tested exclusively with antigen tests.  
162 Variables other than SARS-CoV-2 infection are assumed to be perfectly measured in all  
163 simulations.

#### 164 Data generation process

165 To generate realistic data consistent with the DAG shown in **Box 2**, we generated 1,000 datasets  
166 (each with 1,000,000 observations) that simulated a cumulative prevalence of SARS-CoV-2  
167 infection of ~12.2%,<sup>43</sup> including an asymptomatic infection prevalence of ~35%,<sup>44</sup> and a  
168 cumulative prevalence of fully vaccinated individuals of ~54.6%.<sup>45,46</sup> In addition, we simulated  
169 the proportion of individuals who reported using any SARS-CoV-2 diagnostic test (either NAATs  
170 or antigen tests) within 30 days in the aforementioned survey (~27.7%).<sup>31</sup> Each node in the DAG

171 was generated conditionally on its parent nodes using the models shown in **Table 1**, with  
172 parameters for these models selected based on the available literature whenever possible (**Table**  
173 **S1**). Importantly, although the simulations were designed to represent an outpatient setting, similar  
174 results can be expected for hospital-based TND studies, as the data generating structure may be  
175 similar for both scenarios (**Box 2**).

## 176 Data analysis

177 After generating the data, we first created classical and alternative TND samples from each  
178 simulated dataset by selecting either symptomatic and tested individuals or all tested individuals,  
179 respectively. Second, we estimated the  $OR_{COVID}$  (in the classical samples) and the  $OR_{infect}$  (in the  
180 alternative samples) using logistic regression models conditional on the set of measured  
181 confounders ( $C$ ). For these models, we used the true SARS-CoV-2 infection status as the outcome  
182 variable when evaluating the potential for collider bias and uncontrolled confounding by HSBs,  
183 and the measured SARS-CoV-2 infection status, when incorporating the potential for differential  
184 outcome misclassification. Third, to estimate the true value of the target parameters ( $RR_{COVID}$  and  
185  $RR_{infect}$ ), we generated two counterfactual populations, each consisting of 100,000,000  
186 individuals, representing scenarios in which everyone was either vaccinated or unvaccinated.  
187 Finally, we estimated the bias by subtracting the true values of the target parameters from the  
188 exponentiated mean of the  $\log(OR)$  estimates obtained from the 1,000 simulated datasets (denoted  
189 as  $\widehat{OR}_{COVID}$  or  $\widehat{OR}_{infect}$ ). Additionally, we report the Monte Carlo standard error (MCSE, the  
190 standard deviation of the estimated  $\log(ORs)$ ) and the average standard error (aSE, the average of  
191 the standard error estimates of the  $\log(ORs)$ ).

192 To investigate the potential for larger biases, we iterated over the processes described above, each  
193 time varying the assumed strength of the relationships between the simulated variables.  
194 Specifically, we varied the magnitude of the association between  $H$  and  $V$  (parameter  $\beta_2$  in **Table**  
195 **1**), between  $H$  and both  $I = 1$  and  $I = 2$  (parameters  $\gamma_{1,2}$  and  $\gamma_{2,2}$ , respectively), as well as the  
196 relationships of  $I = 1$  and  $I = 2$  with  $S$  ( $\delta_4$  and  $\delta_5$ , respectively). We also varied the coefficient  
197 for the interaction term of  $I = 2$  and  $V$  with  $S$  ( $\delta_6$ ), and the strengths of the relationships between  
198  $H$  and  $T$  ( $\theta_2$ ), between  $V$  and  $T$  ( $\theta_3$ ), and between  $S$  and  $T$  ( $\theta_4$ ). We adjusted these parameters  
199 according to the direction of the association between the independent and dependent variables.  
200 Specifically, for parameters representing a positive association (i.e.,  $OR > 1$ ), the strength was  
201 increased by units of 1 from 1.5 to 10.5. Conversely, for parameters representing a negative  
202 association (i.e.,  $OR < 1$ ), the strength was decreased from 0.95 to 0.05 by units of 0.1. We also  
203 varied the intercepts for  $T$  ( $\theta_0$ ) and  $I = 2$  ( $\gamma_{2,0}$ ), aiming for a baseline prevalence of testing from  
204 0.25 to 0.7 and for a baseline prevalence of acute SARS-CoV-2 infection from 0.05 to 0.5. Finally,  
205 we simultaneously varied the strength of two, and then three, of the most influential parameters  
206 (i.e.,  $\beta_2$ ,  $\theta_3$ , and the intercept for  $I = 2$ ). It should be noted that any adjustment to these parameters  
207 could lead to changes in the proposed prevalences for all simulated variables.

208 All analyses were performed using R (version 4.2.2, R Foundation for Statistical Computing,  
209 Vienna, Austria, 2022).<sup>47</sup>

## 210 *Results*

211 When we assessed the potential for collider bias and uncontrolled confounding by HSBs we found  
212 a "true value" for  $RR_{COVID}$  of 0.149 and an estimated  $\widehat{OR}_{COVID}$  of 0.141 (MCSE and aSE = 0.019;  
213 bias = -0.008). On the other hand, the "true value" for  $RR_{infect}$  was 0.142, with an estimated

214  $\widehat{OR}_{infect}$  of 0.125 (MCSE and aSE = 0.014; bias = -0.016). The results after varying the  
215 strength of selected parameters for this scenario, either individually or simultaneously, are shown  
216 in **Figures 2-3** and **Tables S2-S3**. In every case, the classical TND outperformed the alternative  
217 in terms of bias, with the biases for  $\widehat{OR}_{COVID}$  and  $\widehat{OR}_{infect}$  ranging from -0.034 to -0.001 and  
218 from -0.211 to 0.728, respectively. When we incorporated imperfect tests, we found estimates  
219 for  $\widehat{OR}_{COVID}$  of 0.154 (MCSE = 0.019; aSE = 0.018; bias = 0.005) and  $\widehat{OR}_{infect}$  of 0.146  
220 (MCSE and aSE = 0.014; bias = 0.004), respectively. However, after varying the strength of  
221 selected parameters for this scenario, either individually or simultaneously, we found larger bias  
222 for  $\widehat{OR}_{infect}$  (ranging from -0.188 to 0.766) than for  $\widehat{OR}_{COVID}$  (ranging from -0.005 to 0.018)  
223 (**Figures 4-5** and **Tables S4-S5**).

## 224 **Discussion**

225 The TND has become a preferred method for assessing VE against pathogens such as influenza,  
226 largely due to its seamless integration with existing laboratory-based surveillance systems.<sup>6</sup> More  
227 recently, this observational study design has been widely used to estimate VE against COVID-  
228 19.<sup>21</sup> This widespread application was made possible primarily by the extensive use of SARS-  
229 CoV-2 testing during the pandemic, which generated large amounts of potential data for TND  
230 studies.<sup>21</sup> However, the use of these data for VE estimation poses unique validity challenges.<sup>21</sup>

231 Originally, the TND was proposed as an efficient way to identify a control group (test-negative  
232 controls) for individuals who contracted the vaccine-targeted infection (test-positive cases) while  
233 also accounting for confounding by HSBs.<sup>5,7,8</sup> However, to effectively control for such bias in  
234 TND studies, researchers must assume that individuals seeking care and undergoing testing have

235 comparable HSBs.<sup>5,7,8</sup> In the pre-COVID-19 era, testing for diseases such as influenza was  
236 primarily driven by clinical indications and focused on those who actively sought care for  
237 symptoms.<sup>48</sup> This arguably made it easier for researchers to assume that individuals enrolled in  
238 TND studies had comparable HSBs, provided the same clinical definition was used for cases and  
239 controls. However, this paradigm shifted with COVID-19, when testing criteria were expanded to  
240 identify asymptomatic infections, often on a “mandatory” basis, in order to break transmission  
241 chains.<sup>32</sup> In this article, we have shown that TND applications that ignore this fact and include  
242 individuals regardless of their symptoms (i.e., using the alternative TND) can potentially introduce  
243 collider stratification bias, uncontrolled confounding by HSBs, and differential misclassification  
244 of the outcome relative to the exposure status.

245 Our simulation study, based on educated guesses for parameter values and representing a scenario  
246 in which the classical TND would yield unbiased estimates for its target parameter, showed only  
247 minor bias in the alternative TND setting. However, we also showed that the inclusion of  
248 asymptomatic individuals can lead to substantial bias in some scenarios. For example, our  
249 simulations showed that as the effect of HSBs on vaccination increases ( $OR > 1$ ), the estimated  
250  $\widehat{OR}_{infect}$  can become progressively closer to the null relative to its target parameter,  $RR_{infect}$ ,  
251 leading to further underestimation of VE when expressed as  $1 - OR \times 100$ . Similarly, in settings  
252 where vaccination status is more negatively correlated with testing ( $OR < 1$ ), the  $\widehat{OR}_{infect}$  would  
253 also be progressively biased towards the null. In addition, we observed that a higher baseline  
254 prevalence of SARS-CoV-2 infection would lead to a greater bias away from the null of  $\widehat{OR}_{infect}$ ,  
255 resulting in an overestimation of VE. We also found that these biases may be exacerbated by the  
256 introduction of differential outcome misclassification when different diagnostic approaches are

257 used for symptomatic and asymptomatic individuals. Of note, the TND is well known to be  
258 particularly susceptible to misclassification bias compared to cohort and traditional case-control  
259 studies.<sup>49</sup> It is also important to mention that if one were to condition on the reason for testing or  
260 restrict the study sample to asymptomatic individuals, we would expect to observe the same bias  
261 described here, as all biasing pathways would remain open.

262 It could be argued that the biases discussed here may be only relevant to retrospective TND studies  
263 that rely on routinely collected health data (i.e., data collected without predetermined research  
264 questions<sup>50</sup>). For example, some TND studies using administrative data sources may have included  
265 asymptomatic individuals simply because of a lack of information on reasons for testing, as  
266 acknowledged by some authors.<sup>14,15</sup> However, it should be noted that some retrospective TND  
267 studies of COVID-19 VE intentionally included asymptomatic individuals to estimate VE against  
268 infection, even when data on symptoms were available.<sup>10-12,16,17</sup> In fact, some prospective TND  
269 studies (i.e., those collecting primary research data) conducted during the COVID-19 pandemic  
270 also included individuals regardless of symptoms.<sup>18-20</sup> That said, the potential for inclusion of  
271 asymptomatic individuals may be influenced not only by the data source, but also by the testing  
272 practices in the specific context or time frame in which the study is conducted.

273 The changing landscape of COVID-19 testing practices throughout the pandemic further highlights  
274 the need for proper attention to context in TND studies. At the onset of the COVID-19 pandemic,  
275 testing was primarily NAAT-based and focused on symptomatic individuals.<sup>32</sup> However, as the  
276 pandemic progressed, testing guidelines were modified to support mass testing of asymptomatic  
277 individuals as a tool for pandemic containment.<sup>32</sup> Any TND study conducted under these  
278 circumstances, whether prospective or retrospective, would be at risk of the bias described here if

279 a clinical definition was not included in the study's eligibility criteria. Thus, we believe that the  
280 issues discussed here are relevant not only to TND studies using routinely collected health and  
281 administrative data, but also to all studies conducted in settings where the rationale for testing  
282 extends beyond purely clinical reasons. **Box 4** provides a list of suggested strategies to minimize  
283 bias in TND studies conducted in such scenarios.

284 It is worth noting that there may be some specific circumstances in which the magnitude of the  
285 biases discussed here could be attenuated by other features of the study design, particularly those  
286 that allow for the selection of a population with comparable HSBs. For example, TND studies  
287 focusing on booster effectiveness may be less susceptible to HSBs-related bias because subjects  
288 in these studies typically have completed a primary immunization schedule and are therefore  
289 expected to have more similar HSBs.<sup>21</sup> Likewise, some might argue that hospital-based TND  
290 studies are likely to include individuals with more homogeneous HSBs because only those  
291 evaluated in clinical settings are eligible. However, as discussed elsewhere,<sup>7</sup> it may be unrealistic  
292 to assume that all hospitalized individuals have the same levels of HSBs. In addition, it should be  
293 noted that not all SARS-CoV-2 tests performed in hospitals under pandemic conditions were  
294 triggered by COVID-19-like symptoms; for example, some institutions mandated universal  
295 screening on admission.<sup>33,34</sup> Consequently, hospital-based TND studies that include all individuals  
296 tested regardless of the reason for testing,<sup>13,51</sup> would be expected to have biases similar to those  
297 discussed here.

298 This study has numerous strengths but also carries limitations. Among the strengths, our simulation  
299 study was illustrated by DAGs, which helps to clarify the potential sources of bias. In addition,  
300 while this article focuses on the COVID-19 setting, the issues discussed here are also relevant to

301 TND studies using the alternative approach in the context of other infectious diseases. This may  
302 be particularly true in scenarios of widespread testing, such as during epidemics or pandemics,  
303 where testing protocols and preferences are influenced by clinical and public health considerations,  
304 or in situations where self-testing for various infections is available.

305 In terms of limitations, the strength of the relationships depicted in the DAG may vary. For  
306 example, the path between vaccination and testing ( $V \rightarrow T$ ) may be weak in some contexts.  
307 Nevertheless, collider bias could still occur through these nodes because unobservable factors,  
308 including HSBs, could confound the association between  $V$  and  $T$ . Another limitation lies in the  
309 values assigned to the parameters in our simulations. Although we relied on existing literature,  
310 these values are still estimates. However, varying these parameter values supported our theory-  
311 based hypothesis that relevant biases may occur in some settings. Finally, our study focused on  
312 specific issues related to the inclusion of asymptomatic individuals in TND studies. However, we  
313 did not assess additional complexities, such as the possibility of differential measurement error in  
314 exposure, outcome, or covariate status based on testing rationale, or the nuances in data quality  
315 and challenges specific to their respective sources, such as clinical versus other settings.<sup>21</sup>

## 316 **Conclusions**

317 In conclusion, the inclusion of asymptomatic individuals in TND studies of COVID-19 VE may  
318 lead to collider stratification bias, uncontrolled confounding by HSBs, and differential  
319 misclassification of the outcome relative to exposure status. Researchers designing or applying the  
320 TND for VE estimation need to be aware of these potential biases. Further research is needed to  
321 identify additional design or analytic strategies to control for biases related to HSBs that may  
322 improve the validity and utility of the TND for estimating VE against infection.



323 **Data Availability Statement**

324 Code and a sample simulated dataset are available and can be accessed here:

325 <https://ortizbrizuela.github.io/projects/>

326 **Acknowledgements**

327 Work supported by the Canadian Institutes of Health Research Project Grant ECP-184178

328 (awarded to MES, DT, JM, CJ). MES holds the Canada Research Chair in Causal Inference and

329 Machine Learning in Health Science. MC holds a Chercheur Boursier Junior 1 Award from the

330 Fonds de recherche du Québec-Santé (FRQS). DT holds a Chercheur Boursier Junior 2 Award

331 from FRQS. E-OB holds a Doctoral Training Award from FRQS.

332 **Conflicts of interest:**

333 None.

## 334 References

- 335 1. Cowling BJ, Sullivan SG. A concern over terminology in vaccine effectiveness studies.  
336 *Euro Surveill* 2018; **23**(10).
- 337 2. Patel MM, Jackson ML, Ferdinands J. Postlicensure Evaluation of COVID-19 Vaccines.  
338 *JAMA* 2020; **324**(19): 1939-40.
- 339 3. Prugger C, Spelsberg A, Keil U, Erviti J, Doshi P. Evaluating covid-19 vaccine efficacy  
340 and safety in the post-authorisation phase. *BMJ* 2021; **375**: e067570.
- 341 4. Barouch DH. Covid-19 Vaccines - Immunity, Variants, Boosters. *N Engl J Med* 2022;  
342 **387**(11): 1011-20.
- 343 5. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine  
344 effectiveness. *Vaccine* 2013; **31**(17): 2165-8.
- 345 6. Chua H, Feng S, Lewnard JA, et al. The Use of Test-negative Controls to Monitor Vaccine  
346 Effectiveness: A Systematic Review of Methodology. *Epidemiology* 2020; **31**(1): 43-64.
- 347 7. Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical Basis of the Test-Negative  
348 Study Design for Assessment of Influenza Vaccine Effectiveness. *Am J Epidemiol* 2016; **184**(5):  
349 345-53.
- 350 8. Schnitzer ME. Estimands and Estimation of COVID-19 Vaccine Effectiveness Under the  
351 Test-Negative Design: Connections to Causal Inference. *Epidemiology* 2022; **33**(3): 325-33.
- 352 9. Song S, Madewell ZJ, Liu M, Longini IM, Yang Y. Effectiveness of SARS-CoV-2  
353 Vaccines against Omicron Infection and Severe Events: A Systematic Review and Meta-Analysis  
354 of Test-Negative Design Studies. *medRxiv* 2023: 2023.02.16.23286041.
- 355 10. Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against  
356 SARS-CoV-2 Infection in Qatar. *N Engl J Med* 2021; **385**(24): e83.
- 357 11. Chemaitelly H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine  
358 effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. *Nat*  
359 *Med* 2021; **27**(9): 1614-21.
- 360 12. Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine  
361 effectiveness against the SARS-CoV-2 Delta variant in Qatar. *Nat Med* 2021; **27**(12): 2136-43.
- 362 13. Bruxvoort KJ, Sy LS, Qian L, et al. Effectiveness of mRNA-1273 against delta, mu, and  
363 other emerging variants of SARS-CoV-2: test negative case-control study. *BMJ* 2021; **375**:  
364 e068848.
- 365 14. Skowronski DM, Setayeshgar S, Zou M, et al. Comparative Single-Dose mRNA and  
366 ChAdOx1 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2,  
367 Including Variants of Concern: Test-Negative Design, British Columbia, Canada. *J Infect Dis*  
368 2022; **226**(1): 485-96.
- 369 15. Ionescu IG, Skowronski DM, Sauvageau C, et al. BNT162b2 Effectiveness Against Delta  
370 and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2 in Adolescents Aged  
371 12-17 Years, by Dosing Interval and Duration. *J Infect Dis* 2023; **227**(9): 1073-83.
- 372 16. Andrejko KL, Pry J, Myers JF, et al. Prevention of Coronavirus Disease 2019 (COVID-  
373 19) by mRNA-Based Vaccines Within the General Population of California. *Clin Infect Dis* 2022;  
374 **74**(8): 1382-9.

- 375 17. Hitchings MDT, Ranzani OT, Torres MSS, et al. Effectiveness of CoronaVac among  
376 healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus,  
377 Brazil: A test-negative case-control study. *Lancet Reg Health Am* 2021; **1**: 100025.
- 378 18. Li XN, Huang Y, Wang W, et al. Effectiveness of inactivated SARS-CoV-2 vaccines  
379 against the Delta variant infection in Guangzhou: a test-negative case-control real-world study.  
380 *Emerg Microbes Infect* 2021; **10**(1): 1751-9.
- 381 19. Singh C, Naik BN, Pandey S, et al. Effectiveness of COVID-19 vaccine in preventing  
382 infection and disease severity: a case-control study from an Eastern State of India. *Epidemiol Infect*  
383 2021; **149**: e224.
- 384 20. Thiruvengadam R, Awasthi A, Medigeshi G, et al. Effectiveness of ChAdOx1 nCoV-19  
385 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-  
386 negative, case-control study and a mechanistic study of post-vaccination immune responses.  
387 *Lancet Infect Dis* 2022; **22**(4): 473-82.
- 388 21. Shi X, Li KQ, Mukherjee B. Current Challenges With the Use of Test-Negative Designs  
389 for Modeling COVID-19 Vaccination and Outcomes. *Am J Epidemiol* 2023; **192**(3): 328-33.
- 390 22. Pearl J. Causal diagrams for empirical research. *Biometrika* 1995; **82**(4): 669-88.
- 391 23. Hernán MA RJ. Chapter 2. Randomized experiments. *Causal Inference: What If*: Chapman  
392 & Hall/CRC; 2020: 13-24.
- 393 24. Hernán MA RJ. Chapter 6. Graphical representation of causal effects. *Causal Inference:*  
394 *What If*: Chapman & Hall/CRC; 2020: 69-82.
- 395 25. Vandembroucke JP, Pearce N. Test-Negative Designs: Differences and Commonalities  
396 with Other Case-Control Studies with "Other Patient" Controls. *Epidemiology* 2019; **30**(6): 838-  
397 44.
- 398 26. Ciocanea-Teodorescu I, Nason M, Sjolander A, Gabriel EE. Adjustment for Disease  
399 Severity in the Test-Negative Study Design. *Am J Epidemiol* 2021; **190**(9): 1882-9.
- 400 27. Dean NE, Hogan JW, Schnitzer ME. Covid-19 Vaccine Effectiveness and the Test-  
401 Negative Design. *N Engl J Med* 2021; **385**(15): 1431-3.
- 402 28. Infante-Rivard C, Cusson A. Reflection on modern methods: selection bias-a review of  
403 recent developments. *Int J Epidemiol* 2018; **47**(5): 1714-22.
- 404 29. Didelez V, Kreiner S, Keiding N. Graphical Models for Inference Under Outcome-  
405 Dependent Sampling. *Statistical Science* 2010; **25**(3): 368-87, 20.
- 406 30. Hernán MA RJ. Chapter 3. Observational studies. *Causal Inference: What If*: Chapman &  
407 Hall/CRC; 2020: 25-40.
- 408 31. Rader B, Gertz A, Iuliano AD, et al. Use of At-Home COVID-19 Tests - United States,  
409 August 23, 2021-March 12, 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**(13): 489-94.
- 410 32. Peeling RW, Heymann DL, Teo YY, Garcia PJ. Diagnostics for COVID-19: moving from  
411 pandemic response to control. *Lancet* 2022; **399**(10326): 757-68.
- 412 33. Stadler RN, Maurer L, Aguilar-Bultet L, et al. Systematic screening on admission for  
413 SARS-CoV-2 to detect asymptomatic infections. *Antimicrob Resist Infect Control* 2021; **10**(1): 44.
- 414 34. Talbot TR, Hayden MK, Yokoe DS, et al. Asymptomatic screening for severe acute  
415 respiratory coronavirus virus 2 (SARS-CoV-2) as an infection prevention measure in healthcare  
416 facilities: Challenges and considerations. *Infect Control Hosp Epidemiol* 2023; **44**(1): 2-7.
- 417 35. Dinnes J, Deeks JJ, Adriano A, et al. Rapid, point-of-care antigen and molecular-based  
418 tests for diagnosis of SARS-CoV-2 infection. *Cochrane Database Syst Rev* 2020; **8**(8): CD013705.


- 419 36. Hohl CM, Hau JP, Vaillancourt S, et al. Sensitivity and Diagnostic Yield of the First SARS-  
420 CoV-2 Nucleic Acid Amplification Test Performed for Patients Presenting to the Hospital. *JAMA*  
421 *Netw Open* 2022; **5**(10): e2236288.
- 422 37. Antonelli M, Penfold RS, Canas LDS, et al. SARS-CoV-2 infection following booster  
423 vaccination: illness and symptom profile in a prospective, observational community-based case-  
424 control study. *J Infect* 2023.
- 425 38. Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-  
426 vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective,  
427 community-based, nested, case-control study. *Lancet Infect Dis* 2022; **22**(1): 43-55.
- 428 39. Grana C, Ghosn L, Evrenoglou T, et al. Efficacy and safety of COVID-19 vaccines.  
429 *Cochrane Database Syst Rev* 2022; **12**(12): CD015477.
- 430 40. Government of Canada. (n.d.). Testing of vaccinated populations. Public Health Agency  
431 of Canada. Retrieved May 10, 2023, from [https://www.canada.ca/en/public-  
432 health/services/diseases/coronavirus-disease-covid-19/testing-screening-contact-tracing/testing-  
433 vaccinated-populations.html](https://www.canada.ca/en/public-health/services/diseases/coronavirus-disease-covid-19/testing-screening-contact-tracing/testing-vaccinated-populations.html).
- 434 41. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative  
435 Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time  
436 Since Exposure. *Ann Intern Med* 2020; **173**(4): 262-7.
- 437 42. Keogh RH, Shaw PA, Gustafson P, et al. STRATOS guidance document on measurement  
438 error and misclassification of variables in observational epidemiology: Part 1-Basic theory and  
439 simple methods of adjustment. *Stat Med* 2020; **39**(16): 2197-231.
- 440 43. World Health Organization. (n.d.). United States of America: WHO Coronavirus (COVID-  
441 19) Dashboard. Retrieved from (April 10, 2023): <https://covid19.who.int/region/amro/country/us>.
- 442 44. Sah P, Fitzpatrick MC, Zimmer CF, et al. Asymptomatic SARS-CoV-2 infection: A  
443 systematic review and meta-analysis. *Proc Natl Acad Sci U S A* 2021; **118**(34).
- 444 45. U.S. Census Bureau. (n.d.). U.S. and World Population Clock. United States Census  
445 Bureau. Retrieved from (April 10, 2023): <https://www.census.gov/popclock/>.
- 446 46. Mathieu E, Ritchie H, Ortiz-Ospina E, et al. A global database of COVID-19 vaccinations.  
447 *Nat Hum Behav* 2021; **5**(7): 947-53.
- 448 47. R Core Team (2022). R: A language and environment for statistical computing. R  
449 Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>.
- 450 48. Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical Practice Guidelines by the Infectious  
451 Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and  
452 Institutional Outbreak Management of Seasonal Influenza. *Clin Infect Dis* 2019; **68**(6): e1-e47.
- 453 49. De Smedt T, Merrall E, Macina D, Perez-Vilar S, Andrews N, Bollaerts K. Bias due to  
454 differential and non-differential disease- and exposure misclassification in studies of vaccine  
455 effectiveness. *PLoS One* 2018; **13**(6): e0199180.
- 456 50. Benchimol EI, Smeeth L, Guttman A, et al. The REporting of studies Conducted using  
457 Observational Routinely-collected health Data (RECORD) statement. *PLoS Med* 2015; **12**(10):  
458 e1001885.
- 459 51. Tan CY, Chiew CJ, Pang D, et al. Vaccine effectiveness against Delta, Omicron BA.1, and  
460 BA.2 in a highly vaccinated Asian setting: a test-negative design study. *Clin Microbiol Infect* 2023;  
461 **29**(1): 101-6.
- 462 52. Wu F, Yuan Y, Li Y, et al. The acceptance of SARS-CoV-2 rapid antigen self-testing: A  
463 cross-sectional study in China. *J Med Virol* 2023; **95**(1): e28227.

- 464 53. Centers for Disease Control and Prevention. (2021, April 2). CDC updates travel guidance  
465 for fully vaccinated people. Retrieved from (on April 13, 2023):  
466 <https://www.cdc.gov/media/releases/2021/p0402-travel-guidance-vaccinated-people.html>.  
467 54. Occupational Safety and Health Administration. (n.d.). Employer Rights and  
468 Responsibilities Following a Federal OSHA Inspection. U.S. Department of Labor. Retrieved May  
469 10, 2023, from <https://www.osha.gov/sites/default/files/publications/OSHA4159.pdf>.  
470 55. World Health O. Evaluation of COVID-19 vaccine effectiveness: interim guidance, 17  
471 March 2021. CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization, 2021.  
472

"Alternative" Test-Negative Design (TND)	An observational study design commonly used to estimate vaccine effectiveness (VE) against infection (whether symptomatic or asymptomatic). This design includes all individuals tested for the pathogen targeted by the vaccine under study, irrespective of their symptom status. VE is then estimated by comparing the odds of vaccination between individuals with positive and negative test results (test-positive cases and test-negative controls, respectively).
"Classical" TND	An observational study design commonly used to estimate VE against medically attended and laboratory-confirmed symptomatic infection. It includes individuals who are tested for the pathogen targeted by the vaccine under study due to the presence of symptoms. VE is then estimated by comparing the vaccination odds between individuals with positive and negative test results. Importantly, while both the alternative TND and the classical TND estimate VE, their specific objectives differ. While the alternative TND estimates VE against all infections, symptomatic or asymptomatic, the "classical" TND focuses only on VE against medically attended symptomatic infections. See below for definitions of infection and symptomatic infection.
Identifiability	The ability to express (identify) a counterfactual (causal) quantity, such as a measure of effect, as a function of the distribution of observed data, implying the absence of systematic bias.
Infection	The process by which a specific microorganism — the one targeted by the vaccine under study — invades and multiplies within an individual. An acute infection is usually confirmed by laboratory. Individuals with an infection may be asymptomatic, with no symptoms associated with the infection, or symptomatic, with symptoms associated with the infection. See the definition of “symptomatic infection” for more details.

Symptomatic Infection	This term describes an individual with a laboratory-confirmed infection (e.g., via nucleic acid amplification test) who also exhibit symptoms associated with that specific infection (e.g., fever, cough, or dyspnea in the case of COVID-19).
Target Parameter	The specific true measure of effect that a test-negative design study aims to estimate.
Vaccine Effectiveness	The effect of vaccination on the risk of an infection-related outcome. Specifically, it represents the expected reduction in the risk of an infection-related outcome that is directly attributable to vaccination.

475



This causal Directed Acyclic Graph (DAG) consists of six nodes representing the following random variables:

- 1)  $V$ : Receipt of the COVID-19 vaccine under study (vaccinated [ $V = 1$ ], unvaccinated [ $V = 0$ ]).
- 2)  $I$ : Infection status (no infection [ $I = 0$ ], an illness that presents with COVID-19-like symptoms but tests negative for COVID – such as a non-SARS-CoV-2 infection [ $I = 1$ ], a SARS-CoV-2 infection [ $I = 2$ ]).
- 3)  $S$ : Presence of COVID-19-like symptoms (symptomatic [ $S = 1$ ], asymptomatic [ $S = 0$ ]).
- 4)  $T$ : Whether a SARS-CoV-2 diagnostic test was performed (tested [ $T = 1$ ], not tested [ $T = 0$ ]).
- 5)  $H$ : An indicator of the presence of health and healthcare-seeking behaviors (HSBs) that contribute to a greater probability of seeking medical care if COVID-19-like symptoms develop (HSBs present [ $H = 1$ ], HSBs absent [ $H = 0$ ]).
- 6)  $C$ : A set of measured confounders of the association between vaccination status ( $V$ ) and SARS-CoV-2 infection ( $I = 2$ ), such as age, calendar time, and sex.

---

Directed Acyclic Graph Rationale (\*†)

---



The path  $I \rightarrow S \rightarrow T$  represents the typical sequence of events leading to a COVID-19 diagnosis for a patient presenting with COVID-19-like symptoms. For example, an individual may contract a SARS-CoV-2 infection ( $I = 2$ ) or another type of infection ( $I = 1$ ), develop symptoms ( $S = 1$ ), and subsequently seek care, resulting in COVID-19 testing ( $T = 1$ ). Because this is an observational study, the association between COVID-19 vaccination ( $V$ ) and SARS-CoV-2 infection ( $I = 2$ ) is expected to be confounded by both the presence of HSBs ( $H$ ) and the set of measured confounders ( $C$ ).<sup>7</sup> Specifically, for this demonstration, we assume that individuals who exhibit HSBs ( $H = 1$ ) are more likely to be vaccinated ( $V = 1$ ) and to engage in other healthy or preventive behaviors that may protect them against SARS-CoV-2 infection ( $I = 2$ ). Furthermore, certain individual characteristics, such as advanced age or the presence of comorbidities (i.e., the set of measured confounders  $C$ ), may increase the probability that individuals will be vaccinated ( $V = 1$ ) and the probability that they will become infected with SARS-CoV-2 ( $I = 2$ ).

We also assume that an individual's HSBs ( $H$ ) are influenced by the set of measured confounders ( $C$ ).<sup>7</sup> In turn, these variables ( $H$  and  $C$ ) influence an individual's probability of getting tested (represented by the path  $H \rightarrow T \leftarrow C$ ). For example, older individuals, those with comorbidities, and those exhibiting HSBs ( $H = 1$ ) may be more likely to get tested ( $T = 1$ ) due to fear of potential complications.<sup>52</sup> Additionally, we assume that vaccinated individuals ( $V = 1$ ) may be less likely to get tested ( $T = 1$ ) in some situations. For example, vaccinated individuals ( $V = 1$ ) may attribute their symptoms ( $S = 1$ ) to alternative causes (e.g., allergies or other infections ( $I = 1$ )), or they may be exempt from certain testing policies (e.g., for some travel-related or workplace screening programs<sup>‡</sup>).<sup>40,53,54</sup> Moreover, we consider the possibility that vaccines may reduce symptoms or disease severity (e.g., hospitalization or death).<sup>37-39</sup> Therefore, we allow COVID-19-like symptoms ( $S$ ) to be directly affected by COVID-19 vaccination ( $V$ ). Finally, we consider that the set of measured confounders ( $C$ ) may influence the presence of COVID-19-like symptoms ( $S$ ) (represented by the path  $C \rightarrow S$ ).<sup>44</sup>

#### Notes:

(\*) For a brief introduction to the theory and terminology of DAGs, see **Appendix S1**.

(†) This DAG is applicable to both outpatient- and inpatient-based TND studies. In particular, the "testing" node can represent both hospitalization and testing in hospital-based TND studies (see Schnitzer, M. 2022 for an example).<sup>8</sup>

(‡) **Table S1** lists selected scenarios where testing practices varied between vaccinated and unvaccinated individuals during the pandemic.

**Classical TND \***

$$RR_{COVID} = \left( \frac{P(I = 2, S = 1, T = 1 \mid V = 1, H = 1, C)}{P(I = 2, S = 1, T = 1 \mid V = 0, H = 1, C)} \right)$$

$$OR_{COVID} = \left( \frac{P(I = 2 \mid V = 1, S = 1, T = 1, H = 1, C)}{P(I = 2 \mid V = 0, S = 1, T = 1, H = 1, C)} \right) / \left( \frac{P(I = 1 \mid V = 1, S = 1, T = 1, H = 1, C)}{P(I = 1 \mid V = 0, S = 1, T = 1, H = 1, C)} \right)$$

**Alternative TND ‡**

$$RR_{infect} = \left( \frac{P(I = 2 \mid V = 1, C)}{P(I = 2 \mid V = 0, C)} \right)$$

$$OR_{infect} = \left( \frac{P(I = 2 \mid V = 1, T = 1, C)}{P(I = 2 \mid V = 0, T = 1, C)} \right) / \left( \frac{P(I = 1 \mid V = 1, T = 1, C)}{P(I = 1 \mid V = 0, T = 1, C)} \right)$$

**Notation:**

- $C$ : Confounders
- $H$ : Health and healthcare-seeking behaviors
- $I = 1$ : A test-negative COVID-19-like illness.
- $I = 2$ : SARS-CoV-2 infection
- $S$ : COVID-19-like symptoms
- $T$ : SARS-CoV-2 diagnostic tests

- $V$ : COVID-19 vaccination status

**Notes:**

(\*) In the classical TND, the target parameter is the conditional risk ratio for medically attended and laboratory-confirmed symptomatic COVID-19. Therefore, the population of interest consists of individuals exhibiting HSBs ( $H = 1$ ), with all SARS-CoV-2 infection ( $I = 2$ ), symptoms ( $S = 1$ ), and testing ( $T = 1$ ) being part of the definition of  $RR_{COVID}$ . Furthermore, for  $OR_{COVID}$  to approximate  $RR_{COVID}$ , we require independence between the test-negative state (having some illness that presents with COVID-19-like symptoms – such as an infection non-targeted by the vaccine – and testing) and the vaccination status, conditional on covariates:

$$P(I = 1, S = 1, T = 1 | V = 1, H = 1, C) = P(I = 1, S = 1, T = 1 | V = 0, H = 1, C)$$

(‡) In the alternative TND setting, the target parameter is the conditional risk ratio for SARS-CoV-2 infection ( $I = 2$ ), which includes both symptomatic and asymptomatic individuals. Since the study sample is not restricted to health care seekers, the target population is no longer limited to individuals with HSBs ( $H = 1$ ). Our manuscript provides several reasons why this target parameter may not be identified under the alternative TND, i.e., why  $OR_{infect} \neq RR_{infect}$ .

480 **Box 4.** *Suggested strategies for minimizing bias in TND studies conducted during infectious*  
481 *disease outbreaks.*

- Researchers planning to assess vaccine effectiveness (VE) using the test-negative design (TND) should prioritize the validated – classical – form of this design and therefore must establish common eligibility criteria, including a clinical definition, for both test-positive cases and test-negative controls.
- To effectively implement the validated - classical - form of TND, investigators should collect comprehensive symptoms data prior to testing, including their type and time of onset, as well as data on other reasons for testing. This detailed information may allow investigators to apply tailored eligibility criteria, thereby facilitating comparability of cases and controls in terms of health and healthcare-seeking behaviors (HSBs).
- Because differences in the clinical presentation of vaccine-preventable infectious diseases may affect an individual’s HSBs, researchers are advised not to pool data from inpatient and outpatient settings when using the TND.<sup>6</sup> This step is important to maintain comparability between cases and controls with respect to HSBs.
- When TND studies rely on routinely collected health and administrative data, investigators should attempt to obtain information on symptoms before testing (e.g., at admission for inpatient-based TND studies). If symptom information is not available, investigators may use alternative sources to define clinical eligibility criteria. For example, they may use hospital admission diagnoses as coded by the WHO International Classification of Diseases.
- Investigators should select the most sensitive and specific tests available (e.g., NAATs for COVID-19) to minimize the potential for differential misclassification of outcomes in TND studies. In addition, researchers should consider the potential variation in diagnostic performance due to factors such as the timing of symptom onset. For example, to reduce misclassification errors, especially for infections where viral load peaks near the end of the incubation period, it may be advisable to prioritize testing near the time of symptom onset.<sup>55</sup>
- Given the many potential biases associated with the use of the TND to assess VE against infection, we recommend against using this design for this particular outcome.

482

484 *Table 1: Models used in the simulation study to generate data consistent with the directed acyclic graph shown in Box 2.*


<b>Variable (type)</b>	<b>Distribution / Parameters</b>
<b>C: Confounders (continuous)</b>	Gaussian; $\mu = 40, \sigma = 4$
<b>H: Health and healthcare-seeking behaviors (binary: present vs. absent)</b>	Bernoulli; $\text{expit}(\alpha_0 + \alpha_1 C)$ where: <ul style="list-style-type: none"> <li>• <math>\alpha_0 = -19.4</math>, and <math>\alpha_1 = \log(1.59)</math>.</li> <li>• For a prevalence of <math>H \sim 0.37</math>.</li> </ul>
<b>V: COVID-19 vaccination (binary: vaccinated vs. unvaccinated)</b>	Bernoulli; $\text{expit}(\beta_0 + \beta_1 C + \beta_2 H)$ where: <ul style="list-style-type: none"> <li>• <math>\beta_0 = -12.25</math>, <math>\beta_1 = \log(1.36)</math>, and <math>\beta_2 = \log(1.81)</math>.</li> <li>• For a prevalence of <math>V \sim 0.55</math>.</li> </ul>
<b>I = 1: Non-SARS CoV-2 infection (binary: present vs. absent)</b>	Bernoulli; $\text{expit}(\gamma_{1,0} + \gamma_{1,1} C + \gamma_{1,2} H)$ where: <ul style="list-style-type: none"> <li>• <math>\gamma_{1,0} = -6.7</math>, <math>\gamma_{1,1} = \log(1.12)</math>, and <math>\gamma_{1,2} = \log(0.9)</math>.</li> <li>• For a prevalence of <math>I = 1 \sim 0.10</math>.</li> </ul>
<b>I = 2: SARS-CoV-2 infection (binary: present vs. absent)</b>	Bernoulli; $\text{expit}(\gamma_{2,0} + \gamma_{2,1} C + \gamma_{2,2} H + \gamma_{2,3} V) * (1 - I[I = 1])$ where:

	<ul style="list-style-type: none"> <li>• <math>\gamma_{2,0} = -5.4</math>, <math>\gamma_{2,1} = \log(1.12)</math>, <math>\gamma_{2,2} = \log(0.9)</math>, and <math>\gamma_{2,3} = \log(0.1)</math>.</li> <li>• For a prevalence of <math>I = 2 \sim 0.12</math> and vaccine effectiveness of 90%.</li> <li>• The term <math>(1 - I[I = 1])</math> was incorporated under the assumption that <math>I = 1</math> and <math>I = 2</math> are mutually exclusive.</li> <li>• For simulations incorporating the potential for outcome misclassification, we generated the variable measured SARS-CoV-2 infection (<math>Ix = 2</math>) as shown in Figure 1(c), assuming a sensitivity of 0.97 for NAATs in symptomatic individuals and 0.58 for antigen tests in asymptomatic individuals, with a specificity of 0.99 for both tests.</li> </ul>
<p><b>S: COVID-19-like symptoms (binary: symptomatic vs. asymptomatic)</b></p>	<p>Bernoulli; <math>\text{expit}(\delta_0 + \delta_1 C + \delta_2 C: I[I = 1] + \delta_3 C: I[I = 2] + \delta_4 I[I = 1] + \delta_5 I[I = 2] + \delta_6 I[I = 2]: V) * (I[I = 1] + I[I = 2])</math>  where:</p> <ul style="list-style-type: none"> <li>• <math>\delta_0 = -33.8</math>, <math>\delta_1 = \log(1.2)</math>, <math>\delta_2 = \log(1.93)</math>, <math>\delta_3 = \log(1.93)</math>, <math>\delta_4 = \log(10)</math>, <math>\delta_5 = \log(10)</math>, and <math>\delta_6 = \log(0.52)</math>.</li> <li>• For a prevalence of <math>S \sim 0.65</math> among those with SARS-CoV-2 infection (<math>I = 2</math>).</li> <li>• The term <math>(I[I = 1] + I[I = 2])</math> was included to ensure that symptoms only occur in individuals who have either <math>I = 1</math> or <math>I = 2</math>.</li> </ul>
<p><b>T: COVID-19 diagnostic tests (binary: tested vs. not tested)</b></p>	<p>Bernoulli; <math>\text{expit}(\theta_0 + \theta_1 C + \theta_2 H + \theta_3 V + \theta_4 S) * (1 - I[H = 1, S = 1]) * (1 - I[H = 0, S = 1]) + I[H = 1, S = 1]</math>  where:</p> <ul style="list-style-type: none"> <li>• <math>\theta_0 = -38.8</math>, <math>\theta_1 = \log(2.47)</math>, <math>\theta_2 = \log(1.3)</math>, <math>\theta_3 = \log(0.92)</math>, and <math>\theta_4 = \log(6)</math>.</li> <li>• For a prevalence of <math>T \sim 0.28</math>.</li> </ul>

- The terms  $(1 - I[H = 1, S = 1]) * (1 - I[H = 0, S = 1]) + I[H = 1, S = 1]$  were included to ensure that symptomatic individuals with HSBs would be tested while those without HSBs would not.

486 **Figures**

487 **Figure 1:** Causal-directed acyclic graphs for test-negative-design (TND) studies of COVID-19 vaccine effectiveness: a) the classical  
488 TND setting, b) the alternative TND setting, c) potential for differential misclassification of outcome status in alternative TND studies.




489

490 **Abbreviations:** *C*: Confounders; *H*: health and healthcare-seeking behaviors; *I*: Infection status; *I<sub>x</sub>*: Measured infection status; *S*:  
491 COVID-19-like symptoms; *T*: SARS-CoV-2 diagnostic tests; *V*: COVID-19 vaccination status.

492 **Notes:** The square nodes indicate that the variable is controlled by either the study design or the analysis, while unconditioned nodes  
493 are represented as circles.




494 **Figure 2:** Bias in odds ratio (OR) estimates for symptomatic COVID-19 ( $OR_{COVID}$ ) and SARS-CoV-2 infection ( $OR_{infect}$ ) relative to  
 495 their respective target parameters ( $RR_{COVID}$  and  $RR_{infect}$ ) after varying the strength of selected parameters (assuming perfect SARS-  
 496 CoV-2 diagnostic tests).



497

498 **Abbreviations:** *C*: Confounders; *H*: health and healthcare-seeking behaviors; *I*: Infection status; *I* = 2: SARS-CoV-2 infection status;  
499 OR, odds ratio; RR, risk ratio; *S*: COVID-19-like symptoms; *T*: SARS-CoV-2 diagnostic tests; TND, test-negative design; *V*: COVID-  
500 19 vaccination status.

501 **Figure 3: Bias in odds ratio (OR) estimates for symptomatic COVID-19 ( $OR_{COVID}$ ) and SARS-**  
 502 **CoV-2 infection ( $OR_{infect}$ ) relative to their respective target parameters ( $RR_{COVID}$  and  $RR_{infect}$ )**  
 503 **after simultaneously varying the strength of two selected parameters (assuming perfect SARS-**  
 504 **CoV-2 diagnostic tests).**




505

506 **Abbreviations:** *H*: health and healthcare-seeking behaviors; *I* = 2: SARS-CoV-2 infection status;

507 NAATs, Nucleic Acid Amplification Tests; OR, odds ratio; RR, risk ratio; *T*: SARS-CoV-2

508 diagnostic tests; TND, test-negative design; *V*: COVID-19 vaccination status.


509 *Figure 4: Bias in odds ratio (OR) estimates for symptomatic COVID-19 ( $OR_{COVID}$ ) and SARS-CoV-2 infection ( $OR_{infect}$ ) relative to*  
 510 *their respective target parameters ( $RR_{COVID}$  and  $RR_{infect}$ ) after varying the strength of selected parameters (assuming symptomatic*  
 511 *individuals are tested exclusively with NAATs and asymptomatic individuals are tested exclusively with antigen tests).*



512

513 **Abbreviations:** *C*: Confounders; *H*: health and healthcare-seeking behaviors; *I*: Infection status; *I* = 2: SARS-CoV-2 infection status;  
514 NAATs, Nucleic Acid Amplification Tests; OR, odds ratio; RR, risk ratio; *S*: COVID-19-like symptoms; *T*: SARS-CoV-2 diagnostic  
515 tests; TND, test-negative design; *V*: COVID-19 vaccination status.

516 **Figure 5:** Bias in odds ratio (OR) estimates for symptomatic COVID-19 ( $OR_{COVID}$ ) and SARS-CoV-2  
 517 infection ( $OR_{infect}$ ) relative to their respective target parameters ( $RR_{COVID}$  and  $RR_{infect}$ ) after  
 518 simultaneously varying the strength of two selected parameters (assuming symptomatic individuals are  
 519 tested exclusively with NAATs and asymptomatic individuals are tested exclusively with antigen tests).



520

521 **Abbreviations:** *H*: health and healthcare-seeking behaviors; *I* = 2: SARS-CoV-2 infection status;  
 522 NAATs, Nucleic Acid Amplification Tests; OR, odds ratio; RR, risk ratio; *T*: SARS-CoV-2 diagnostic  
 523 tests; TND, test-negative design; *V*: COVID-19 vaccination status.

524

525

[---]